• Theravance Biopharma posted Q1 2026 revenue of USD 17.7 million, up 15% year over year.
• Net loss narrowed to USD 4.9 million, or USD 0.10 per share, from USD 13.6 million, or USD 0.27 per share, a year earlier.
• Non-GAAP net income from operations swung to USD 0.6 million from a non-GAAP operating loss of USD 8.6 million a year earlier, while cash, cash equivalents and marketable securities climbed to USD 394.7 million with no debt.
• Viatris-recorded YUPELRI US net sales rose 7% year over year to USD 62.4 million; all Hatch-Waxman litigation tied to YUPELRI was resolved following a March settlement with Mankind Pharma.
• Management reiterated confidence in earning a USD 100 million 2026 TRELEGY milestone, citing Q1 2026 GSK-reported net sales of USD 873 million, up 2% year over year, while restructuring targets a roughly 60% cut in operating expenses with full run-rate savings expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF53671) on May 07, 2026, and is solely responsible for the information contained therein.